Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.78 |
| ▸ | POLB | P06746 | 1/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.62 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.57 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.55 |
| ▸ | BRD4 | O60885 | 2/20 | 0.54 |
| ▸ | BRD2 | P25440 | 1/20 | 0.54 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.54 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1137191 | 0.87 | BRD4 (0.70) | MAPTPOLBKMT2AMEN1TP53 | |
| SCHEMBL4984011 | 0.85 | MAPT (0.59) | MAPTPOLBKMT2AMEN1TP53 | |
| SCHEMBL4996296 | 0.85 | MAPT (0.59) | MAPTPOLBKMT2AMEN1TP53 | |
| SCHEMBL3349244 | 0.84 | EGLN1 (0.68) | MAPTPOLBKMT2AMEN1TP53 | |
| SCHEMBL6919159 | 0.84 | EGLN1 (0.68) | MAPTPOLBKMT2AMEN1TP53 | |
| SCHEMBL4997385 | 0.84 | MAPT (0.61) | MAPTPOLBKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL4990920 | 0.84 | MAPT (0.61) | MAPTPOLBKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL19788434 | 0.84 | ATM (0.69) | MAPTPOLBKMT2AMEN1TP53 | |
| SCHEMBL25392998 | 0.83 | KDM4E (0.71) | MAPTPOLBKMT2AMEN1TP53 | |
| SCHEMBL19788435 | 0.83 | KDM4E (0.71) | MAPTPOLBKMT2AMEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | ENCYSIVE PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | C3AR1, C5, C5AR1 | MAPT 4654/4885POLB 4248/4885KMT2A 2978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.